Definitions of pulmonary exacerbation in people with cystic fibrosis: a scoping review

被引:0
|
作者
Almulhem, Maryam [1 ,2 ]
Ward, Christopher [1 ]
Haq, Iram [1 ,3 ]
Gray, Robert D. [4 ]
Brodlie, Malcolm [1 ,3 ]
机构
[1] Newcastle Univ, Translat & Clin Res Inst, Newcastle Upon Tyne, England
[2] King Faisal Univ, Coll Appl Med Sci, Al Hasa, Saudi Arabia
[3] Newcastle Tyne Hosp NHS Fdn Trust, Great North Childrens Hosp, Paediat Resp Med, Newcastle Upon Tyne, England
[4] Univ Glasgow, Sch Infect & Immun, Glasgow, Scotland
关键词
pulmonary exacerbation; cystic fibrosis; definition; QUALITY-OF-LIFE; CHILDREN; ADULTS; TRIAL; AZITHROMYCIN; RATIONALE; FREQUENCY; OUTCOMES; DESIGN; FEV1;
D O I
10.1136/bmjresp-2024-002456
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background Pulmonary exacerbations (PExs) are clinically important in people with cystic fibrosis (CF). Multiple definitions have been used for PEx, and this scoping review aimed to identify the different definitions reported in the literature and to ascertain which signs and symptoms are commonly used to define them.Methods A search was performed using Embase, MEDLINE, Cochrane Library, Scopus and CINAHL. All publications reporting clinical trials or prospective observational studies involving definitions of PEx in people with CF published in English from January 1990 to December 2022 were included. Data were then extracted for qualitative thematic analysis.Results A total of 14 039 records were identified, with 7647 titles and abstracts screened once duplicates were removed, 898 reviewed as full text and 377 meeting the inclusion criteria. Pre-existing definitions were used in 148 publications. In 75% of papers, an objective definition was used, while 25% used a subjective definition, which subcategorised into treatment-based definitions (76%) and those involving clinician judgement (24%). Objective definitions were subcategorised into three groups: those based on a combination of signs and symptoms (50%), those based on a predefined combination of signs and symptoms plus the initiation of acute treatment (47%) and scores involving different clinical features each with a specific weighting (3%). The most common signs and symptoms reported in the definitions were, in order, sputum production, cough, lung function, weight/appetite, dyspnoea, chest X-ray changes, chest sounds, fever, fatigue or lethargy and haemoptysis.Conclusion We have identified substantial variation in the definitions of PEx in people with CF reported in the literature. There is a requirement for the development of internationally agreed-upon, standardised and validated age-specific definitions. Such definitions would allow comparison between studies and effective meta-analysis to be performed and are especially important in the highly effective modulator therapy era in CF care.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis
    Louw, Jacoba Johanna
    Toelen, Jaan
    Proesmans, Marijke
    Vermeulen, Francois
    Billen, Jaak
    de Boeck, Kris
    EUROPEAN JOURNAL OF PEDIATRICS, 2012, 171 (01) : 139 - 142
  • [32] Serum procalcitonin is not an early marker of pulmonary exacerbation in children with cystic fibrosis
    Jacoba Johanna Louw
    Jaan Toelen
    Marijke Proesmans
    François Vermeulen
    Jaak Billen
    Kris de Boeck
    European Journal of Pediatrics, 2012, 171 : 139 - 142
  • [33] Factors influencing treatment response of pulmonary exacerbation in children with cystic fibrosis
    Singh, Jagdev
    Robinson, Paul
    Pandit, Chetan
    Kennedy, Brendan
    Weldon, Beth
    Bailey, Brooke
    John, Merilyn
    Fitzgerald, Dominic
    Selvadurai, Hiran
    MINERVA PEDIATRICS, 2023, : 245 - 252
  • [34] Lung Clearance Index in Children with Cystic Fibrosis during Pulmonary Exacerbation
    Walicka-Serzysko, Katarzyna
    Postek, Magdalena
    Milczewska, Justyna
    Sands, Dorota
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (21)
  • [35] Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis
    Wojsyk-Banaszak, I
    Sobkowiak, P.
    Jonczyk-Potoczna, K.
    Narozna, B.
    Langwinski, W.
    Szczepanik, M.
    Kycler, Z.
    Breborowicz, A.
    Szczepankiewicz, A.
    MEDIATORS OF INFLAMMATION, 2019, 2019
  • [36] Defining pulmonary exacerbation in children with non-cystic fibrosis bronchiectasis
    Kapur, Nitin
    Masters, Ian B.
    Morris, Peter S.
    Galligan, John
    Ware, Robert
    Chang, Anne B.
    PEDIATRIC PULMONOLOGY, 2012, 47 (01) : 68 - 75
  • [37] Pulmonary exacerbation inflammatory phenotypes in adults with cystic fibrosis
    Dong, Kang
    Huh, Sung Moon
    Lam, Grace Y.
    Jang, Jiah
    Franciosi, Alessandro N.
    Wilcox, Pearce G.
    Quon, Bradley S.
    JOURNAL OF CYSTIC FIBROSIS, 2023, 22 (02) : 306 - 312
  • [38] Factors Contributing to Vitamin D Status at Hospital Admission for Pulmonary Exacerbation in Adults With Cystic Fibrosis
    Bhimavarapu, Anirudh
    Deng, Qiao
    Bean, Marta
    Lee, Nick
    Ziegler, Thomas R.
    Alvarez, Jessica
    Tangpricha, Vin
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2021, 361 (01) : 75 - 82
  • [39] Self-management interventions for people with pulmonary fibrosis: a scoping review
    Lee, Joanna Y. T.
    Tikellis, Gabriella
    Dowman, Leona
    Jones, Arwel W.
    Hoffman, Mariana
    Mellerick, Christie R.
    Malaguti, Carla
    Khor, Yet H.
    Holland, Anne E.
    EUROPEAN RESPIRATORY REVIEW, 2023, 32 (170)
  • [40] Pulmonary Aspergillosis in People with Cystic Fibrosis
    Schwarz, C.
    Eschenhagen, P. N.
    Mainz, J. G.
    Schmidergall, T.
    Schuette, H.
    Romanowska, E.
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 45 (01) : 128 - 140